Autres langues Jiangsu Recbio Technology Co., Ltd.

Actions

2179

CNE1000057K9

Cours en clôture Hong Kong S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
9,13 ^CNY	0,00 %		-1,72 %	-15,93 %

27/03	Jiangsu Recbio Technology Co. et Shanghai Rongsheng Biotech Co. signent un accord de coopération stratégique sur un nouveau projet de vaccin adjuvant. signent un accord de coopération stratégique sur le projet de nouveau vaccin adjuvant	CI
21/03	La perte de Jiangsu Recbio Technology se réduit en 2023	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	27/03
Jiangsu Recbio Technology's Loss Narrows in 2023	21/03
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines	29/12
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	29/12
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine	29/12
Jiangsu Recbio Technology to Extend Validity Period of Share Sale	28/12
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index	18/09/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
China Approves Recbio's Clinical Trial Application for Shingles Vaccine	27/07/23
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	26/07/23
Jiangsu Recbio Technology Co., Ltd. - Inclusion of Recbio in the MSCI China Small Cap Index	18/05/23
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index	17/05/23
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments	11/05/23
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	20/04/23
Pfizer signs strategic cooperation pact with China's Sinopharm	13/04/23
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee	03/04/23
Certain H Shares of Jiangsu Recbio Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/03/23
Mongolia Grants Emergency Approval for Jiangsu Recbio's Recombinant COVID-19 Vaccine	21/03/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Jiangsu Recbio Technology Co., Ltd.

Actions

2179

CNE1000057K9

Autres langues

Filtres